BR112022015523A2 - Anticorpos anti-hepsina e seus usos - Google Patents

Anticorpos anti-hepsina e seus usos

Info

Publication number
BR112022015523A2
BR112022015523A2 BR112022015523A BR112022015523A BR112022015523A2 BR 112022015523 A2 BR112022015523 A2 BR 112022015523A2 BR 112022015523 A BR112022015523 A BR 112022015523A BR 112022015523 A BR112022015523 A BR 112022015523A BR 112022015523 A2 BR112022015523 A2 BR 112022015523A2
Authority
BR
Brazil
Prior art keywords
antibodies
antihepsin
hepsin
hepsin antibodies
methods
Prior art date
Application number
BR112022015523A
Other languages
English (en)
Inventor
Blake P Johnson
Timothy J O?Brien
Original Assignee
Navaux Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navaux Inc filed Critical Navaux Inc
Publication of BR112022015523A2 publication Critical patent/BR112022015523A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
    • G01N2470/04—Sandwich assay format

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPOS ANTI-HEPSINA E SEUS USOS. O presente pedido descreve métodos para a obtenção de anticorpos anti-Hepsina, a anticorpos anti-Hepsina, a métodos para a varredura da atividade de anticorpos anti-Hepsina, a composições farmacêuticas dos anticorpos anti-Hepsina, kits contendo os anticorpos anti-Hepsina e a métodos de utilização dos anticorpos anti-Hepsina para o diagnóstico de um câncer.
BR112022015523A 2020-02-05 2021-02-03 Anticorpos anti-hepsina e seus usos BR112022015523A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062970626P 2020-02-05 2020-02-05
PCT/US2021/016409 WO2021158660A2 (en) 2020-02-05 2021-02-03 Anti-hepsin antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112022015523A2 true BR112022015523A2 (pt) 2022-09-27

Family

ID=77200525

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015523A BR112022015523A2 (pt) 2020-02-05 2021-02-03 Anticorpos anti-hepsina e seus usos

Country Status (11)

Country Link
US (1) US20230236192A1 (pt)
EP (1) EP4100062A4 (pt)
JP (1) JP2023512782A (pt)
KR (1) KR20220137696A (pt)
CN (1) CN115427075A (pt)
AU (1) AU2021215999A1 (pt)
BR (1) BR112022015523A2 (pt)
CA (1) CA3169809A1 (pt)
IL (1) IL295258A (pt)
MX (1) MX2022009584A (pt)
WO (1) WO2021158660A2 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625165A2 (en) * 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US8383351B2 (en) * 2008-06-11 2013-02-26 Oxford Brookes University Antibody to inhibin/ activin β-B subunit
EP3617228A1 (en) * 2009-01-16 2020-03-04 University of Exeter Antibody against aspergillus
EP2491059B1 (en) * 2009-10-22 2015-02-25 F.Hoffmann-La Roche Ag Anti-hepsin antibodies and methods using same
WO2011161189A1 (en) * 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
CN102093479B (zh) * 2010-11-29 2012-10-03 侯宗柳 抗人血管内皮生长因子受体2的重组嵌合抗体
WO2012174569A2 (en) * 2011-06-17 2012-12-20 The Board Of Trustees Of The University Of Arkansas New markers for early diagnosis of ovarian cancer, monitoring during therapy, and new therapy options during and after chematherapy
US20180305702A1 (en) * 2015-09-15 2018-10-25 Advaxis, Inc. Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment

Also Published As

Publication number Publication date
CN115427075A (zh) 2022-12-02
KR20220137696A (ko) 2022-10-12
JP2023512782A (ja) 2023-03-29
AU2021215999A1 (en) 2022-09-01
US20230236192A1 (en) 2023-07-27
IL295258A (en) 2022-10-01
EP4100062A2 (en) 2022-12-14
EP4100062A4 (en) 2024-05-22
MX2022009584A (es) 2022-10-07
WO2021158660A3 (en) 2021-09-23
WO2021158660A2 (en) 2021-08-12
CA3169809A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
BR112019018685A8 (pt) Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
BR112023015045A2 (pt) Agonistas de receptores de gpcr, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
BR112022003589A2 (pt) Conjugado de anticorpo-fármaco compreendendo anticorpo contra ror1 humano e uso para o mesmo
BR112020024412A8 (pt) Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação
BR112017023849A2 (pt) anticorpos anti-ox40 e métodos de uso dos mesmos
BR112014020826A8 (pt) Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
BR112015023262A2 (pt) anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112021015238A8 (pt) Novos anticorpos de ligação a cd40
ECSP088778A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR112023001733A2 (pt) Anticorpos anti-ceacam5 e conjugados e usos dos mesmos
BR112017026191A2 (pt) compostos tricíclicos e seu uso como inibidores de fosfodiesterase
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
BR112022024045A2 (pt) Moduladores il-17a
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
CO2022001194A2 (es) Moléculas de unión a claudina-6 y usos de las mismas
BR112022023983A2 (pt) Compostos terapêuticos
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
BR112021011325A2 (pt) Derivados de rapamicina
BR112022021748A2 (pt) Compostos e composições para inibir a atividade de hif2a e seus métodos de uso
BR112022018678A2 (pt) Degradadores de mdm2 e usos dos mesmos